Gilead Raises Full-Year Sales Guidance as 18% HIV Business Growth Drives Q3 Revenue Beat
nashnova research
Gilead Sciences posted Q3 revenue of $8.3 billion, beating estimates by nearly $500 million on the back of 18% HIV growth; the company lifted full-year product-sales guidance to $31.0–31.3 billion — but also widened its adjusted loss outlook, weighed down by a string of acquisition-related R&D charges.
Where exactly did the quarter beat?
Q3 revenue hit $8.3 billion, up from $7.77 billion a year ago and well above the $7.81 billion analyst consensus.
Full-year product-sales guidance rose to $31.0–31.3 billion, roughly $900 million above the prior range and far ahead of FactSet's $30.54 billion consensus.
This means → Wall Street had been modelling Gilead too conservatively; the company effectively forced a model reset.
What is driving 18% HIV growth?
CEO Daniel O'Day pointed to HIV prevention drugs — PrEP, or pre-exposure prophylaxis — with sales nearly doubling year-over-year.
This means → growth is no longer just about treating existing patients; the prevention market is opening an entirely new revenue layer.
Trodelvy (an oncology drug) and Livdelzi also contributed, though declining sales of COVID treatment Veklury and cell-therapy products partially offset the gains.
Why are profits falling despite the revenue beat?
Net income came in at $2.43 billion, down roughly 20% year-over-year; adjusted EPS, however, was $2.55, above the $2.19 consensus.
Full-year adjusted loss guidance widened from $0.30–0.65 per share to $0.85–1.20 per share — far worse than the $0.40 analysts had expected.
In plain terms = revenue is rising but profit is shrinking, because Gilead is spending heavily to buy its future — one-time in-process R&D charges (IPR&D — the cost booked when you acquire drug programs still in development) are dragging the bottom line.
What did these acquisitions actually buy?
Four deals are on the list: Arcellx, Tubulis GmbH, Ouro Medicines, and a recent $1.28 billion purchase of an oral IL-23R inhibitor program — a new class of oral anti-inflammatory drug — from PepStar Therapeutics.
Together, these charges account for roughly $9.88 per share — almost the entire reason the loss guidance widened.
This reflects a deliberate strategic bet on three fronts: oncology, inflammation, and cell therapy, as Gilead tries to build a second growth engine beyond HIV.
What does the market watch next?
Whether HIV's 18% growth rate holds is the near-term valuation pivot — the prevention-drug market ceiling is still far off, but competitors are entering.
Progress on oncology and inflammation pipeline launches will determine whether the acquisitions were money well spent or overpaid.
In plain terms = the revenue story now checks out; the next question is when profits catch up.
市场有风险，内容仅供研究参考，不构成投资建议。